20:30 , Oct 12, 2018 |  BioCentury  |  Emerging Company Profile

Targeting GPCRs, Ab Initio

Ab Initio Biotherapeutics Inc. is using its biochemistry expertise and an integrated set of three platforms to purify GPCRs in clinically relevant conformations for producing anti-GPCR antibodies. Antibodies can act on their targets with better...
21:34 , Dec 16, 2016 |  BC Week In Review  |  Company News

Pfizer, Ab Initio deal

The companies partnered to use Ab Initio's platform to discover antibodies against an undisclosed target in the GPCR superfamily. Pfizer has exclusive, worldwide rights to develop and commercialize antibodies developed under the deal. Ab Initio...
07:00 , Oct 1, 2015 |  BC Innovations  |  Translation in Brief

Miniaturizing immunotherapy

A Stanford University team has engineered a small protein antagonist of the PD-1 pathway that could compete with the panoply of antibodies in development or on the market because it can penetrate tumors better. Newco...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

J&J other, pharmaceuticals news

Johnson & Johnson launched the fourth incubator in its JLABS network, located in South San Francisco, and named the first 10 companies in residence. J&J said the incubator can accommodate up to 50 startups. Eight...
01:47 , Mar 4, 2015 |  BC Extra  |  Company News

J&J launches second Bay Area JLABS incubator

Johnson & Johnson (NYSE:JNJ) launched the fourth incubator in its JLABS network, located in South San Francisco, Calif., and named the first 10 companies in residence. J&J said the incubator can accommodate up to 50...
07:00 , Sep 10, 2007 |  BioCentury  |  Tools & Techniques

Metabasis' quantum hop

The pharmaceutical industry rarely uses free energy perturbation-based methods in computer-aided drug design because these methods have low throughput, require a high level of user expertise and do not always produce results of the desired...
08:00 , Dec 18, 2000 |  BioCentury  |  Emerging Company Profile

Prospect Genomics: Virtual docking

Virtual drug screening is a technology that many researchers hope will one day replace, to some extent, biochemical high throughput screening assays. While the basic technology for virtual drug screening has been available for years,...
07:00 , Apr 10, 2000 |  BioCentury  |  Tools & Techniques

Time Out! Human genome hype rivals Y2K

While the human genome project was initially considered by many to be a waste of government money, the subsequent excitement over the potential drugs and diagnostics to come out of the effort has silenced its...